BI-1347
CAS No. : 2163056-91-3
| Size | Price | Stock |
|---|---|---|
| 5mg | $100 | In-stock |
| 10mg | $160 | In-stock |
| 50mg | $560 | In-stock |
| 100mg | $950 | In-stock |
| 200 mg | Get quote | |
| 500 mg | Get quote | |
| We match the lowest price on market. | ||
We offer a substantial discount on larger orders, please inquire via [email protected]
or Fax: (86)21-58955996
Inquiry for price and availability only. Please place your order via our email or fax.
| Cat. No. : | HY-120350 |
| M.Wt: | 356.42 |
| Formula: | C22H20N4O |
| Purity: | >98 % |
| Solubility: | DMSO : 125 mg/mL (ultrasonic) |
BI-1347 is an orally active, selective and potent CDK8 inhibitor (IC50=1.1 nM). BI-1347 shows anti-tumoral activity[1][2].
IC50 & Target:IC50: 1.1 nM (CDK8)[1]
In Vitro:BI-1347 (150 nM; 44 h) enhances granzyme B (GZMB+) production in mouse splenic NK cells[2].
BI-1347 (0.1 nM-10 μM; 24 h) treatment increases perforin secretion from NK92MI cells[2].
In Vivo:BI-1347 (oral gavage; 10 mg/kg; once daily; 30 d) modulates STAT1 S727 phosphorylation and shows anti-tumor activity in vivo[2].
BI-1347 (oral gavage; 10 mg/kg) intermittent schedule and BI-8382 continuous treatment combination treatment increases efficacy compared to each monotherapy in the mammary carcinoma EMT6 model[2].
Lorem ipsum dolor sit amet, consectetur adipisicing elit. Autem earum hic iste maiores, nam neque rem suscipit. Adipisci consequatur error exercitationem fugit ipsam optio qui, quibusdam repellendus sed vero! Debitis.
Inquiry Information- Product Name:
- BI-1347
- Cat. No.:
- HY-120350
- Quantity:
Your information is safe with us.